biote vs Niagen Bioscience
BTMD and NAGE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BTMD and NAGE compare
Niagen Bioscience is the larger company, worth 4.6 times as much as biote ($159M against $34.5M).
On earnings, biote is cheaper: it trades at 9.6× trailing earnings, against 16.8× for Niagen Bioscience.
Niagen Bioscience grew revenue faster over the last twelve months (−1.9% versus −7.8% for biote).
Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with 3.2% at biote.
Niagen Bioscience scores higher on the StockData Score (14 against 8 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BTMD | NAGE |
|---|---|---|
| Size and price | ||
| Market cap | $34.5M | $159M |
| Share price | $0.960 | $2.01 |
| Change, 1 year | −63.1% | −71.2% |
| Change, 5 years | −90.1% | −59.1% |
| Beta (5Y) | 2.00 | 1.08 |
| Employees | 223 | 117 |
| StockData Score | ||
| Total score | 8 | 14 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 9.6× (better) | 16.8× |
| P/S | 0.2× (better) | 1.3× |
| P/B | – | 1.9× |
| EV/EBITDA | 8.2× (better) | 18.8× |
| P/FCF | 1.7× | – |
| FCF yield | 57.6% | – |
| Fair value | $3.21 | $2.30 |
| Margin of safety | 70.1% (better) | 12.6% |
| Growth | ||
| Revenue growth (TTM) | −7.8% | −1.9% (better) |
| Revenue growth, 5Y average | – | 16.9% |
| Net income growth (TTM) | −81.3% | −49.9% (better) |
| EPS growth (TTM) | −88.9% | −50.0% (better) |
| Profitability | ||
| Gross margin | 68.6% (better) | 63.9% |
| Operating margin | 8.0% (better) | 3.9% |
| Net margin | 3.2% | 8.4% (better) |
| FCF margin | 10.8% | – |
| Return on equity | – | 13.3% |
| Return on invested capital | 45.7% (better) | 44.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 5.93 | – |
| Current ratio | 1.43 | 5.93 (better) |
| Altman Z-score | 1.86 | 3.87 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Payout ratio | 19.9% | – |
| Buyback yield | – | 3.4% |
| Shareholder yield | 0.00% | 3.4% (better) |
| Ownership | ||
| Held by institutions | 36.6% | 40.4% |
| Held by insiders | 23.3% | 5.1% |
| Insider net buying, 12 months | $202K (better) | $0 |
| Short interest, % of float | 3.1% | 5.8% |
Go deeper
- BTMD stock overview
- BTMD income statement
- BTMD valuation and score
- NAGE stock overview
- NAGE income statement
- NAGE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.